In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Histogen launches aesthetics biz

This article was originally published in The Rose Sheet

Executive Summary

Skin-, hair- and nail-care products under development are built upon regenerative medicine company'sReGenica complex, extracted from proprietary bioreactor process in which newborn fibroblasts - connective tissue cells involved in wound healing - are grown under embryonic-like conditions. Composed of naturally secreted growth factors, antioxidants and other synergistic bio-products, Regenica was associated with improved overall skin condition, compared with control group, in 49-subject study when applied following an ablative cosmetic laser procedure. Follow-up studies are exploring the treatment's usefulness post-laser-resurfacing and in topical skin and hair anti-aging applications, firm says. "The market for next-generation, novel cosmeceuticals is rapidly evolving," notes Lawrence A. Rheins, Ph.D., president of new Histogen Aesthetics division. "There is a continuing need for adjunct palliative skin conditioning products for use following all sorts of minimally invasive cosmetic procedures ... by physicians engaged in aesthetic medicine." Histogen is optimistic that "robust controlled scientific data to support claims" will help it stand out from crowd. The Estee Lauder Companies/Allergan also made clinical validation a top priority in creating Clinique Medical skin care for patients undergoing non-surgical cosmetic procedures (1"The Rose Sheet" Oct. 20, 2008, p. 4)

Related Content

UsernamePublicRestriction

Register

RS015748

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel